MARIA LOERA-QUINTANILLA: Open Payments
NPI 1124295035 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,420 in 75 payments from 10 companies in 2025. Trend: 2023 $798 · 2024 $817 · 2025 $1,420
Food & beverage: $1,420
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $456 |
| Alkermes, Inc. | 14 | $310 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $227 |
| Lundbeck LLC | 6 | $111 |
| Neurocrine BioSciences, Inc. | 6 | $111 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| ABBVIE INC. | 2 | $47 |
| Galderma Laboratories, L.P. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: UZEDY, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, AUSTEDO XR, LYBALVI, INGREZZA, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
